$990.32
−0.55%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1,002.11
From 52W high−6.48%
Volume243308.00
Market cap$61.96B
P/E (TTM)46.8x
P/S (TTM)14.9x
Div yield—
Key dataSep 18, 2026
Open
$1,002.11
From 52W high
−6.48%
Volume
243308.00
Market cap
$61.96B
ValuationView details →
P/E (Fwd)
118.3x
EV/EBITDA
43.3x
P/E (TTM)
46.8x
RSI (14)
53.0
MomentumView details →
1D Return
−0.55%
YTD Return
+18.39%
SummaryUpdated Jun 1, 2026
argenx SE (NASDAQ:ARGX) is a Dutch biotechnology company founded in 2008 and headquartered in Amsterdam, Netherlands. The company went public on NASDAQ in May 2017. argenx has evolved from a research-stage biotechnology company into a commercial-stage biopharmaceutical company with its flagship product VYVGART achieving significant commercial success. The company specializes in developing antibody-based therapies for autoimmune diseases, with a particular focus on conditions affecting the neuromuscular system. argenx has established itself as a leader in targeting the neonatal Fc receptor (FcRn) pathway, a novel mechanism for treating antibody-mediated autoimmune diseases.
Similar companies
Latest newsMore news →
argenx completed its acquisition of Forte Biosciences, Inc., adding the anti-CD122 antibody FB102 to its immunology pipeline.24d agoArgenx announced successful trial results for its biotech product, causing its stock to soar.30d agoargenx announced positive topline results from the Phase 3 ALKIVIA trial of VYVGART Hytrulo (efgartigimod) in autoimmune myositis, meeting its primary endpoint of mean Total Improvement Score at Week 52 in combined IMNM and DM patients (p=0.0011).34d ago